Elevated systemic monocyte chemoattractrant protein-1 in hepatic steatosis without significant hepatic inflammation

Experimental and Molecular Pathology

Volumn 91, Issue 3, 2011, Pages 780-783

  Kirovski, Georgi ^a   Dorn, Christoph ^a   Huber, Hanna ^a   Moleda, Lukas ^a   Niessen, Catrin ^a   Wobser, Hella ^a   Schacherer, Doris ^a   Buechler, Christa ^a   Wiest, Reiner ^a   Hellerbrand, Claus ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Adipose tissue; Chemokine; Hepatic steatosis; MCP 1; NAFLD; NASH

Indexed keywords

GLUCOSE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BODY MASS; CONTROLLED STUDY; ECHOGRAPHY; GENE EXPRESSION REGULATION; GENE FUNCTION; GLUCOSE BLOOD LEVEL; HEPATITIS; INTRAABDOMINAL FAT; LIPID STORAGE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOPHYSIOLOGY; PORTAL VEIN BLOOD FLOW; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ADIPOSE TISSUE; ANIMALS; BODY MASS INDEX; CHEMOKINE CCL2; DIET, HIGH-FAT; FATTY LIVER; INFLAMMATION; LIVER; MICE; OBESITY;

MUS;

EID: 80054872645     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2011.08.001     Document Type: Article

References (26)

1. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346:1221-1231.
2. Bedogni G., Miglioli L., Masutti F., Tiribelli C., Marchesini G., Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005, 42:44-52.
3. Bellentani S., Scaglioni F., Marino M., Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 2010, 28:155-161.
4. Bose T., Alvarenga J.C., Tejero M.E., Voruganti V.S., Proffitt J.M., Freeland-Graves J.H., Cole S.A., Comuzzie A.G. Association of monocyte chemoattractant protein-1 with adipocyte number, insulin resistance and liver function markers. J. Med. Primatol. 2009, 38:418-424.
5. Bradley R.L., Jeon J.Y., Liu F.F., Maratos-Flier E. Voluntary exercise improves insulin sensitivity and adipose tissue inflammation in diet-induced obese mice. Am. J. Physiol. Endocrinol. Metab. 2008, 295:E586-E594.
6. Chew G.T., Gan S.K., Watts G.F. Revisiting the metabolic syndrome. Med. J. Aust. 2006, 185:445-449.
7. Dorn C., Riener M.O., Kirovski G., Saugspier M., Steib K., Weiss T.S., Gabele E., Kristiansen G., Hartmann A., Hellerbrand C. Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int. J. Clin. Exp. Pathol. 2010, 3:505-514.
8. Haukeland J.W., Damas J.K., Konopski Z., Loberg E.M., Haaland T., Goverud I., Torjesen P.A., Birkeland K., Bjoro K., Aukrust P. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 2006, 44:1167-1174.
9. Imamura M., Ogawa T., Sasaguri Y., Chayama K., Ueno H. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology 2005, 128:138-146.
10. Ito M., Suzuki J., Tsujioka S., Sasaki M., Gomori A., Shirakura T., Hirose H., Ito M., Ishihara A., Iwaasa H., Kanatani A. Longitudinal analysis of murine steatohepatitis model induced by chronic exposure to high-fat diet. Hepatol. Res. 2007, 37:50-57.
11. Jiang J., Torok N. Nonalcoholic steatohepatitis and the metabolic syndrome. Metab. Syndr. Relat. Disord. 2008, 6:1-7.
12. Kanda H., Tateya S., Tamori Y., Kotani K., Hiasa K., Kitazawa R., Kitazawa S., Miyachi H., Maeda S., Egashira K., Kasuga M. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 2006, 116:1494-1505.
13. Kim C.S., Park H.S., Kawada T., Kim J.H., Lim D., Hubbard N.E., Kwon B.S., Erickson K.L., Yu R. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int. J. Obes. (Lond) 2006, 30:1347-1355.
14. Kirovski G., Schacherer D., Wobser H., Huber H., Niessen C., Beer C., Scholmerich J., Hellerbrand C. Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonographic characteristics. Int. J. Clin. Exp. Med. 2010, 3:202-210.
15. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A.J., Natale S., Forlani G., Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
16. Marra F., DeFranco R., Grappone C., Milani S., Pastacaldi S., Pinzani M., Romanelli R.G., Laffi G., Gentilini P. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am. J. Pathol. 1998, 152:423-430.
17. Muhlbauer M., Bosserhoff A.K., Hartmann A., Thasler W.E., Weiss T.S., Herfarth H., Lock G., Scholmerich J., Hellerbrand C. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003, 125:1085-1093.
18. Novo E., Marra F., Zamara E., Valfre di B.L., Monitillo L., Cannito S., Petrai I., Mazzocca A., Bonacchi A., De Franco R.S., Colombatto S., Autelli R., Pinzani M., Parola M. Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 2006, 55:1174-1182.
19. Palmer C., Corpuz T., Guirguis M., O'Toole S., Yan K., Bu Y., Jorgenson J., Talbot M., Loi K., Lloyd A., Zekry A. The effect of obesity on intrahepatic cytokine and chemokine expression in chronic hepatitis C infection. Gut 2010, 59:397-404.
20. Reynolds K., He J. Epidemiology of the metabolic syndrome. Am. J. Med. Sci. 2005, 330:273-279.
21. Schnabl B., Choi Y.H., Olsen J.C., Hagedorn C.H., Brenner D.A. Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab. Invest. 2002, 82:323-333.
22. Seki E., de Minicis S., Inokuchi S., Taura K., Miyai K., van Rooijen N., Schwabe R.F., Brenner D.A. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009, 50:185-197.
23. Tamura Y., Sugimoto M., Murayama T., Ueda Y., Kanamori H., Ono K., Ariyasu H., Akamizu T., Kita T., Yokode M., Arai H. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2195-2201.
24. Weisberg S.P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., Charo I., Leibel R.L., Ferrante A.W. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest. 2006, 116:115-124.
25. Wobser H., Dorn C., Weiss T.S., Amann T., Bollheimer C., Buttner R., Scholmerich J., Hellerbrand C. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell. Res. 2009, 19:996-1005.
26. Yang M.H., Wu F.X., Xie C.M., Qing Y.F., Wang G.R., Guo X.L., Tang Z., Zhou J.G., Yuan G.H. Expression of CC chemokine ligand 5 in patients with rheumatoid arthritis and its correlation with disease activity and medication. Chin. Med. Sci. J. 2009, 24:50-54.